Amgen AI Adoption Tracker
Last updated: August 9, 2026
Overview
Amgen has positioned itself as a leader in biotechnology AI transformation, leveraging artificial intelligence across drug discovery, clinical development, and manufacturing operations [1]. The company describes this as a 'hinge moment' where technology and biotechnology converge to revolutionize medicine development [2]. Under the leadership of Chief Technology Officer David Reese and Senior Vice President of AI and Data Sean Bruich, Amgen has implemented comprehensive AI initiatives including the ATOMIC platform for clinical trial optimization, generative biology partnerships with companies like Generate Biomedicines, and advanced computational infrastructure including the Freyja supercomputer at deCODE genetics [3][4]. These efforts span from administrative productivity tools like Microsoft Copilot adopted by 20,000 employees to sophisticated protein design using NVIDIA's BioNeMo platform [5].
AI Maturity Index
Radar Comparison
Peer Comparison: Amgen vs healthcare
Based on 66 companies in sector
| Dimension | Amgen | Sector Avg | Diff |
|---|---|---|---|
| Adoption | 4.0 | 3.7 | +0.3 |
| Proficiency | 4.0 | 3.5 | +0.5 |
| Impact | 4.0 | 3.6 | +0.4 |
| Overall | 4.0 | 3.6 | +0.4 |
Key Metrics
AI Initiatives
AMPLIFY Protein Language Model
December 2025
AI-powered protein language model developed with Mila Institute
Open-source protein language model that uses sequence to predict function, enabling faster protein design and making advanced protein design more accessible to scientists
ATOMIC Platform
2025
Machine learning model for clinical trial site selection and optimization
Analytical Trial Optimization Module that analyzes extensive data to predict optimal clinical trial sites, resulting in 3x faster enrollment at highly ranked sites according to internal analysis
NVIDIA BioNeMo Collaboration
January 2024
Partnership to build generative AI models for drug discovery using Freyja supercomputer
Deployment of NVIDIA DGX SuperPOD supercomputer named Freyja at deCODE genetics in Iceland to analyze extensive human datasets for drug targets and biomarker discovery
Microsoft Copilot Enterprise Deployment
2024
Company-wide deployment of generative AI productivity tools
Early adoption of Microsoft Copilot by 20,000 employees to streamline administrative tasks and enhance productivity across all operational levels
AWS Generative AI Manufacturing Solutions
November 2023
Expansion of AWS partnership to create AI-based manufacturing solutions
Collaboration to develop generative AI solutions for drug manufacturing, including connected digital platform using Amazon SageMaker for real-time data analysis and predictive maintenance
Frequently Asked Questions
Amgen uses AI across multiple stages of drug discovery, including generative biology for protein design, the ATOMIC platform for clinical trial optimization, and partnerships with companies like Generate Biomedicines and NVIDIA to accelerate molecule discovery and development timelines.
ATOMIC (Analytical Trial Optimization Module) is a machine learning model that analyzes extensive data to predict optimal clinical trial sites, resulting in 3x faster enrollment at highly ranked sites and helping to diversify clinical trial populations.
Amgen has deployed AI tools to approximately 20,000 employees, primarily through Microsoft Copilot for productivity enhancement, making it one of the early enterprise adopters of generative AI at scale.
Amgen's partnership with Generate Biomedicines has a potential transaction value of $1.9 billion, covering up to 10 programs for AI-powered protein therapeutics discovery across multiple therapeutic areas.
Amgen has established an AI Governance Council and follows the NIST Trustworthy AI framework with seven key principles including safety, security, explainability, privacy enhancement, fairness, accountability, and reliability.
In Application
| Application | Vendor | Use Case |
|---|---|---|
| Microsoft Copilot | Microsoft | Productivity enhancement across administrative tasks for 20,000 employees |
| NVIDIA BioNeMo | NVIDIA | Protein language model training and biologics discovery acceleration |
| Amazon SageMaker | Amazon Web Services | Machine learning model development for manufacturing and clinical analytics |
| ChatGPT Enterprise | OpenAI | Advanced generative AI workflows across biotechnology applications |
Sources
Amgen: AI in Research & Development
From the Office to the Lab, Amgen Uses AI Tools to Unlock Innovation
David Reese bets his career on the 'hinge moment' for AI at Amgen
Follow the Data - ATOMIC Platform
Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow
Artificial Intelligence Vision
AWS Joins Forces With Amgen on Generative AI Solutions
Amgen chooses Generate in $1.9B biobucks deal
Related Companies
About AI Tracker
AI Tracker is a research project by Larridin, the AI execution intelligence platform.
Methodology: We analyze earnings calls, press releases, partnership announcements, and product documentation. All assessments are based solely on publicly available information—no private customer data is used.
Maturity Scoring: Each dimension is rated on a 4-tier scale (Nascent → Emerging → Scaling → Leading) based on evidence from public sources. Industry averages are computed as the median across all tracked companies in the sector.